Mapping biological behaviors by application of longer-lived positron emitting radionuclides.

[1]  Michael V. Knopp,et al.  Multimodal Imaging and Detection Strategy With 124 I-Labeled Chimeric Monoclonal Antibody cG250 for Accurate Localization and Confirmation of Extent of Disease During Laparoscopic and Open Surgical Resection of Clear Cell Renal Cell Carcinoma , 2013, Surgical innovation.

[2]  S. Holm,et al.  Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study , 2012, The Journal of Nuclear Medicine.

[3]  F. M. Nortier,et al.  Radioarsenic from a portable (72)Se/(72)As generator: a current perspective. , 2012, Current radiopharmaceuticals.

[4]  W. Oyen,et al.  PET of Tumors Expressing Gastrin-Releasing Peptide Receptor with an 18F-Labeled Bombesin Analog , 2012, The Journal of Nuclear Medicine.

[5]  D. Goldenberg,et al.  Pretargeted Molecular Imaging and Radioimmunotherapy , 2012, Theranostics.

[6]  M. Cooper,et al.  Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability. , 2012, Bioconjugate chemistry.

[7]  Yin Zhang,et al.  Positron emission tomography imaging of tumor angiogenesis with a 66Ga-labeled monoclonal antibody. , 2012, Molecular pharmaceutics.

[8]  E. Chajduk,et al.  Novel radiochemical separation of arsenic from selenium for 72Se/72As generator. , 2012, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[9]  Sanjiv S Gambhir,et al.  Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging. , 2012, Radiology.

[10]  F. M. Nortier,et al.  Selenium-72 formation via nat Br(p,x) induced by 100 MeV protons: steps towards a novel 72Se/72As generator system. , 2012, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[11]  J. Humm,et al.  Bone Marrow Dosimetry Using 124I-PET , 2012, The Journal of Nuclear Medicine.

[12]  T. Nayak,et al.  PET and MRI of Metastatic Peritoneal and Pulmonary Colorectal Cancer in Mice with Human Epidermal Growth Factor Receptor 1–Targeted 89Zr-Labeled Panitumumab , 2012, The Journal of Nuclear Medicine.

[13]  M. Lubberink,et al.  Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PET , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Yin Zhang,et al.  Positron Emission Tomography Imaging of CD105 Expression with a 64Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA , 2011, PloS one.

[15]  J. Humm,et al.  124I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET , 2011, The Journal of Nuclear Medicine.

[16]  M. Reiss,et al.  PET with the 89Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models , 2011, The Journal of Nuclear Medicine.

[17]  Dimitris Visvikis,et al.  Impact of Tumor Size and Tracer Uptake Heterogeneity in 18F-FDG PET and CT Non–Small Cell Lung Cancer Tumor Delineation , 2011, The Journal of Nuclear Medicine.

[18]  N. Bander,et al.  Targeting the Internal Epitope of Prostate-Specific Membrane Antigen with 89Zr-7E11 Immuno-PET , 2011, The Journal of Nuclear Medicine.

[19]  S. Qaim,et al.  Evaluation of excitation functions of proton, ³He- and α-particle induced reactions for production of the medically interesting positron-emitter bromine-76. , 2011, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[20]  M. Cristofanilli,et al.  Circulating Tumor Cells and PET , 2011, The Journal of Nuclear Medicine.

[21]  J. Tomlinson,et al.  CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer , 2011, International journal of molecular imaging.

[22]  T. Nayak,et al.  86Y based PET radiopharmaceuticals: radiochemistry and biological applications. , 2011, Medicinal chemistry (Shariqah (United Arab Emirates)).

[23]  I. Velikyan.  Positron emitting [68Ga]Ga-based imaging agents: chemistry and diversity. , 2011, Medicinal chemistry (Shariqah (United Arab Emirates)).

[24]  A. Chacko,et al.  Radiopharmaceutical chemistry with iodine-124: a non-standard radiohalogen for positron emission tomography. , 2011, Medicinal chemistry (Shariqah (United Arab Emirates)).

[25]  Xiaoyuan Chen,et al.  New Methods for Labeling RGD Peptides with Bromine-76 , 2011, Theranostics.

[26]  J. Humm,et al.  124I-huA33 Antibody PET of Colorectal Cancer , 2011, The Journal of Nuclear Medicine.

[27]  C. Anderson,et al.  Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy , 2011, Cancer biology & therapy.

[28]  T. Nayak,et al.  In vitro and in vivo pre-clinical analysis of a F(ab')2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers , 2011, EJNMMI research.

[29]  T. Sharp,et al.  Characterization of 64Cu-DOTA-Conatumumab: A PET Tracer for In Vivo Imaging of Death Receptor 5 , 2011, The Journal of Nuclear Medicine.

[30]  S. Larson,et al.  Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen , 2011, Proceedings of the National Academy of Sciences.

[31]  J. Bading,et al.  Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging. , 2011, Bioconjugate chemistry.

[32]  J. Humm,et al.  Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody 124I-cG250 , 2011, The Journal of Nuclear Medicine.

[33]  M. Andersen,et al.  Analysis of manganese tracer kinetics and target tissue dosimetry in monkeys and humans with multi-route physiologically based pharmacokinetic models. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[34]  Yin Zhang,et al.  PET tracers based on Zirconium-89. , 2011, Current radiopharmaceuticals.

[35]  T. Nayak,et al.  HER1-Targeted 86Y-Panitumumab Possesses Superior Targeting Characteristics than 86Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts , 2011, PloS one.

[36]  T. Nayak,et al.  PET imaging of tumor angiogenesis in mice with VEGF‐A–targeted 86Y‐CHX‐A″‐DTPA‐bevacizumab , 2011, International journal of cancer.

[37]  Raffaella Barone,et al.  Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  M. Papisov,et al.  Iodine-124 as a label for pharmacological PET imaging. , 2009, Molecular pharmaceutics.

[39]  Yin Zhang,et al.  Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105 , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  S. Treves,et al.  Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody. , 2011, Nuclear medicine and biology.

[41]  F. Rösch,et al.  72/74As-labeling of HPMA based polymers for long-term in vivo PET imaging. , 2010, Bioorganic & medicinal chemistry letters.

[42]  M. Knopp,et al.  positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results , 2010 .

[43]  Xiankai Sun,et al.  PET with non-standard nuclides. , 2010, Current topics in medicinal chemistry.

[44]  V. Tolmachev,et al.  Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets. , 2010, Current medicinal chemistry.

[45]  A. Wu,et al.  Positive progress in immunoPET--not just a coincidence. , 2010, Cancer biotherapy & radiopharmaceuticals.

[46]  T. Nayak,et al.  Preparation, Biological Evaluation, and Pharmacokinetics of the Human Anti-HER1 Monoclonal Antibody Panitumumab Labeled with 86Y for Quantitative PET of Carcinoma , 2010, Journal of Nuclear Medicine.

[47]  M. Robinson,et al.  Immuno-positron emission tomography in cancer models. , 2010, Seminars in nuclear medicine.

[48]  P. L. Jager,et al.  Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer , 2010, Clinical pharmacology and therapeutics.

[49]  H. Hollema,et al.  89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922 , 2010, Journal of Nuclear Medicine.

[50]  P. Jurek,et al.  Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine , 2010, Nature Protocols.

[51]  F. Wuest,et al.  Iodine-124: A Promising Positron Emitter for Organic PET Chemistry , 2010, Molecules.

[52]  J. Disselhorst,et al.  Pretargeted Immuno–Positron Emission Tomography Imaging of Carcinoembryonic Antigen–Expressing Tumors with a Bispecific Antibody and a 68Ga- and 18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts , 2010, Molecular Cancer Therapeutics.

[53]  Quynh-Thu Le,et al.  Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma , 2010, Clinical Cancer Research.

[54]  W. Oyen,et al.  Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti‐di‐diethylenetriaminepentaacetic acid F(ab′)2 antibody , 2010, Cancer.

[55]  T. Nayak,et al.  PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[56]  Ronald Boellaard,et al.  Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients , 2009, Journal of Nuclear Medicine.

[57]  W. Mcbride,et al.  A Novel Method of 18F Radiolabeling for PET , 2009, Journal of Nuclear Medicine.

[58]  Johan R de Jong,et al.  Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging , 2009, Journal of Nuclear Medicine.

[59]  T. Nayak,et al.  Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. , 2009, Bioconjugate chemistry.

[60]  G. Reischl,et al.  PET Imaging of Prostate Cancer Xenografts with a Highly Specific Antibody against the Prostate-Specific Membrane Antigen , 2009, Journal of Nuclear Medicine.

[61]  Jason S. Lewis,et al.  Bromination from the macroscopic level to the tracer radiochemical level: (76)Br radiolabeling of aromatic compounds via electrophilic substitution. , 2009, Bioconjugate chemistry.

[62]  S. Stone-Elander,et al.  On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model , 2009, Journal of Nuclear Medicine.

[63]  P. Lambin,et al.  Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET , 2008, Journal of Nuclear Medicine.

[64]  W Wang,et al.  Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.

[65]  T. Sharp,et al.  Evaluation of a bromine-76-labeled progestin 16alpha,17alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies. , 2008, Nuclear medicine and biology.

[66]  Michael E Phelps,et al.  Treatment Monitoring by 18F-FDG PET/CT in Patients with Sarcomas: Interobserver Variability of Quantitative Parameters in Treatment-Induced Changes in Histopathologically Responding and Nonresponding Tumors , 2008, Journal of Nuclear Medicine.

[67]  O. Corleta,et al.  bcl-2 expression is not associated with survival in metastatic cutaneous melanoma: A historical cohort study , 2008, World journal of surgical oncology.

[68]  L. Tellmann,et al.  PET imaging problems with the non-standard positron emitters Yttrium-86 and Iodine-124. , 2008, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[69]  D. A. Capretto,et al.  Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. , 2008, Cancer biotherapy & radiopharmaceuticals.

[70]  Tanja Fehm,et al.  Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance , 2008, Breast Cancer Research.

[71]  Jin He,et al.  Vascular Imaging of Solid Tumors in Rats with a Radioactive Arsenic-Labeled Antibody that Binds Exposed Phosphatidylserine , 2008, Clinical Cancer Research.

[72]  T. Ruth,et al.  55Cobalt complexes with pendant carbohydrates as potential PET imaging agents. , 2007, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[73]  M. Brechbiel,et al.  Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. , 2007, Nuclear medicine and biology.

[74]  W. Mcbride,et al.  Bispecific Antibody Pretargeting of Radionuclides for Immuno–Single-Photon Emission Computed Tomography and Immuno–Positron Emission Tomography Molecular Imaging: An Update , 2007, Clinical Cancer Research.

[75]  H. Hollema,et al.  In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft , 2007, Journal of Nuclear Medicine.

[76]  M. Welch,et al.  Small-Animal PET of Tumor Angiogenesis Using a 76Br-Labeled Human Recombinant Antibody Fragment to the ED-B Domain of Fibronectin , 2007, Journal of Nuclear Medicine.

[77]  J. Humm,et al.  Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. , 2007, The Lancet. Oncology.

[78]  A. Koong,et al.  Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[79]  R. Mach,et al.  Synthesis and evaluation of a bromine-76-labeled PPARgamma antagonist 2-bromo-5-nitro-N-phenylbenzamide. , 2006, Nuclear medicine and biology.

[80]  C. R. Leemans,et al.  (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[81]  C. Anderson,et al.  Comparative uptakes and biodistributions of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer. , 2005, Nuclear medicine and biology.

[82]  H. Lundqvist,et al.  Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET. , 2005, Nuclear medicine and biology.

[83]  Robert Jones,et al.  A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake , 2005, Clinical Cancer Research.

[84]  A. Koretsky,et al.  Manganese enhanced magnetic resonance imaging of normal and ischemic canine heart , 2005, Magnetic resonance in medicine.

[85]  E. Oosterwijk,et al.  Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[86]  Sanjiv S Gambhir,et al.  Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. , 2005, Cancer research.

[87]  David C. Dorman,et al.  Manganese Dosimetry: Species Differences and Implications for Neurotoxicity , 2005, Critical reviews in toxicology.

[88]  A. Buck,et al.  Quantitative evaluation of manganese-52m as a myocardial perfusion tracer in pigs using positron emission tomography , 1996, European Journal of Nuclear Medicine.

[89]  P. Santens,et al.  Cobalt-55 positron emission tomography in symptomatic atherosclerotic carotid artery disease: borderzone versus territorial infarcts , 2004, Clinical Neurology and Neurosurgery.

[90]  David E Reichert,et al.  Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. , 2003, Nuclear medicine and biology.

[91]  John Missimer,et al.  Measurement of the extracellular space in brain tumors using 76Br-bromide and PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[92]  R. Boellaard,et al.  Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. , 2003, Cancer biotherapy & radiopharmaceuticals.

[93]  L. Zardi,et al.  Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin , 2002, International journal of cancer.

[94]  Jamal Zweit,et al.  Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. , 2002, Journal of the National Cancer Institute.

[95]  David E Reichert,et al.  Production and purification of gallium-66 for preparation of tumor-targeting radiopharmaceuticals. , 2002, Nuclear medicine and biology.

[96]  M. Spieth,et al.  A tabulated summary of the FDG PET literature. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[97]  S. Larson,et al.  Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. , 2002, Nuclear medicine and biology.

[98]  R. Dierckx,et al.  55Co-EDTA for renal imaging using positron emission tomography (PET): a feasibility study. , 2000, Nuclear medicine and biology.

[99]  G. Denardo,et al.  Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. , 1999, Nuclear medicine and biology.

[100]  J. Korf,et al.  Cobalt-55 positron emission tomography in recurrent ischaemic stroke , 1999, Clinical Neurology and Neurosurgery.

[101]  L. Zardi,et al.  Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. , 1999, Cancer research.

[102]  J. Korf,et al.  Positron emission tomography in primary brain tumours using cobalt-55. , 1997, Nuclear medicine communications.

[103]  H. Lundqvist,et al.  Comparative PET imaging of experimental tumors with bromine-76-labeled antibodies, fluorine-18-fluorodeoxyglucose and carbon-11-methionine. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[104]  J. Baranowska-Kortylewicz,et al.  Prodrugs in site-selective delivery of radiopharmaceuticals. , 1997, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[105]  M. Juweid,et al.  Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22 , 1997, Cancer Immunology, Immunotherapy.

[106]  H. Lundqvist,et al.  Pharmacokinetics and experimental PET imaging of a bromine-76-labeled monoclonal anti-CEA antibody. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[107]  J. Korf,et al.  Pharmacokinetics and dosimetry of cobalt-55 and cobalt-57. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[108]  M J Welch,et al.  RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[109]  D. Goldenberg,et al.  Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. , 1995, Cancer research.

[110]  J. Baynes,et al.  The design and application of residualizing labels for studies of protein catabolism , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[111]  N. Volkow,et al.  PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[112]  D. Wilbur,et al.  Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[113]  S. Sirr,et al.  Comparison of the biodistribution of manganese-54 DTPA and gadolinium-153 DTPA in dogs. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[114]  G. Koren,et al.  Pharmacokinetics of oral and intravenous bromide in normal volunteers. , 1986, Journal of toxicology. Clinical toxicology.

[115]  J. Andrews,et al.  Localization of human colorectal tumor xenografts in the nude mouse with the use of radiolabeled monoclonal antibody. , 1983, Journal of the National Cancer Institute.

[116]  A. Rauws,et al.  The influence of dietary chloride on bromide excretion in the rat. , 1975, Toxicology.

[117]  M. Cikrt.  Biliary excretion of 203Hg, 64Cu, 52Mn, and 210Pb in the rat , 1972 .

[118]  R. Söremark,et al.  Distribution of bromide in mice. An autoradiographic study with Br82 , 1960 .

[119]  J. V. D. Werff.  Clinical investigations on the use of radioactive gallium (Ga66 and Ga67) in bone diseases. , 1954 .

[120]  J. T. van der Werff.  Clinical Investigations on the Use of Radioactive Gallium (Ga66 and Ga67) in Bone Diseases , 1954, Acta radiologica.